文献速递白血病

慢性髓性白血病患者停用酪氨酸激酶抑制剂后分子学复发风险:近十年研究的系统综述与荟萃分析

Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.
PubMed 文献 · Br J Haematol · 2020-02-19

该系统综述与荟萃分析检索Medline和Scopus至2019年4月,评估慢性髓性白血病患者首次和第二次停用酪氨酸激酶抑制剂(TKI)后不同时间段的分子学复发(MolRec)概率及重新获得深度分子学缓解(DMR)的概率。首次停药后0-6、6-12、12-18、18-24个月的MolRec概率分别为35%、8%、3%、3%;第二次停药后0-6、6-12、12-18个月分别为48%、27%、12%;90%的患者重新获得DMR。

要点

  • 首次停药后分子学复发主要集中在最初6个月,概率为35%。
  • 第二次停药后分子学复发时间窗更宽,0-6个月为48%,6-12个月为27%。
  • 分子学复发后90%的患者可重新获得深度分子学缓解。

核心结论

  • 首次停用TKI后分子学复发主要发生在最初6个月,概率为35%。
  • 第二次停用TKI后分子学复发时间窗更宽,0-6、6-12、12-18个月概率分别为48%、27%、12%。
  • 分子学复发后90%的患者可重新获得深度分子学缓解。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline和Scopus数据库至2019年4月。
  • 由三名独立审阅者筛选研究,使用MetaXL软件进行随机效应荟萃分析。

主要发现

  • 首次停药后0-6、6-12、12-18、18-24个月的分子学复发概率分别为35%、8%、3%、3%。
  • 第二次停药后0-6、6-12、12-18个月的分子学复发概率分别为48%、27%、12%。
  • 重新获得深度分子学缓解的患者比例为90%。

临床怎么用

  • 首次停药后应重点监测最初6个月内的分子学复发。
  • 第二次停药后需在更长时间窗内持续监测分子学复发。
  • 分子学复发后多数患者可重新获得深度分子学缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

More than 10 years ago, the first pilot observational study of imatinib discontinuation was reported in chronic myeloid leukaemia (CML) patients in deep molecular response (DMR). Several studies have been published since then, in patients treated with frontline imatinib, or second-generation tyrosine kinase inhibitors (TKI) in first or second line but also on second attempt of TKI discontinuation. Our objective was to estimate, through meta-analyses of the literature data, the probability of molecular recurrence (MolRec) in the time periods of 0-6, 6-12, 12-18 and 18-24 months after a first and second TKI discontinuation and the probability of re-acquisition of DMR after MolRec. The Medline and Scopus databases were searched up to April 2019. The studies were selected by three independent reviewers. Random-effect meta-analyses were conducted using the MetaXL software. The probability of MolRec in the time periods 0-6, 6-12, 12-18 and 18-24 months after the first attempt was respectively 35%, 8%, 3% and 3%, whereas the probability of MolRec in the time periods 0-6, 6-12 and 12-18 after the second attempt was 48%, 27% and 12% respectively. Re-acquisition of a DMR was observed in 90% of patients. Most of the MolRec occur during the first six months in case of a first attempt, whereas the second MolRec occurs over a larger window of time.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dulucq S, Astrugue C, Etienne G, et al. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol. 2020. PMID: 32072631. doi:10.1111/bjh.16408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。